Tandem Diabetes Care (TNDM) Invested Capital (2024 - 2025)

Tandem Diabetes Care (TNDM) posted Invested Capital of $40.7 million for Q1 2025, little changed on a QoQ basis from $40.7 million in Q4 2024.

Tandem Diabetes Care (TNDM) Invested Capital (2024 - 2025) Analysis & Trends

Tandem Diabetes Care's Invested Capital history runs 2 years deep, the most recent figure standing at $40.7 million for Q1 2025.

Quarterly Invested Capital changed N/A year-over-year to $40.7 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $40.7 million (down 66.56% YoY) and the FY2024 annual result came in at $40.7 million, changed N/A from the prior year.
Invested Capital was $40.7 million for Q1 2025 at Tandem Diabetes Care, roughly flat from $40.7 million in the prior quarter.
Across five years, Invested Capital topped out at $40.7 million in Q1 2025 and bottomed at $40.5 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	4.41 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	499.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	1.79 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	41.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	1.41 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	7.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	15.00 Mn
10	Tandem Diabetes Care	1.16 Bn	587.46 Mn	136.79 Mn	-

Download Data